Relevance of donepezil in enhancing learning and memory in special populations: A review of the literature

Journal of Autism and Developmental Disorders

Volumn 37, Issue 10, 2007, Pages 1883-1901

  Yoo, J Helen ^a   Valdovinos, Maria G ^b   Williams, Dean C ^c  

^a Center for Autism and Related Disorders   (United States)

^b DRAKE UNIVERSITY   (United States)

^c Parsons Research Center   (United States)

Author keywords

Acetylcholine; Autism; Donepezil (Aricept)

Indexed keywords

ACETYLCHOLINESTERASE; AMPA RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DIZOCILPINE; DONEPEZIL; GALANTAMINE; MEMANTINE; METHYL BROMIDE; METRIFONATE; N (4 ACETYL 1 PIPERAZINYL) 4 FLUOROBENZAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PHYSOSTIGMINE; PLACEBO; RIVASTIGMINE; SCOPOLAMINE; SCOPOLAMINE METHYL BROMIDE; SILDENAFIL; TACRINE;

AGITATION; ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; AUTISM; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COGNITION; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DOWN SYNDROME; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPOTENSION; HYPOTHESIS; IRRITABILITY; LEARNING; LIVER TOXICITY; MEASUREMENT; MEMORY; MUSCLE CRAMP; NAUSEA; NEUROPATHOLOGY; PRIMATE; PRIORITY JOURNAL; RELIABILITY; REVIEW; RHESUS MONKEY; RODENT; SCHIZOPHRENIA; SIDE EFFECT; SPATIAL DISCRIMINATION; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; VALIDITY; VOMITING;

ALZHEIMER DISEASE; ANIMALS; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTISTIC DISORDER; BRAIN INJURIES; DOWN SYNDROME; HUMANS; INDANS; LEARNING DISORDERS; MEMORY DISORDERS; MENTAL RECALL; NOOTROPIC AGENTS; PIPERIDINES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 35348967477     PISSN: 01623257     EISSN: 15733432     Source Type: Journal    
DOI: 10.1007/s10803-006-0322-8     Document Type: Review

References (127)

1. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders text revision. Washington, DC: Author.
2. Anderson R., & Higgins, G. A. (1997). Absence of central cholinergic deficits in ApoE knockout mice. Psychopharmacology, 132, 135-144.
3. Barnes, C. A., Meltzer, J., Houston, F., Orr, G., McGann, K., & Wenk, G. L. (2000). Chronic treatment of old rats with donepezil or galantamine, effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 99, 17-23.
4. Bauman, M. L., & Kemper, T. L. (1994). Neuroanatomic observations of the brain in autism. In M. L. Bauman, & T. L. Kemper. (Eds.), The neurobiology of autism (pp. 119-145). Baltimore, MD: Johns Hopkins University Press.
5. Berger-Sweeney, J., & Hohmann, C. F. (1997). Behavioral consequences of abnormal cortical development, insights into developmental disabilities. Behavior and Brain Research, 86, 121-142.
6. Bourgeois, J. A., Bahadur, N., & Minjares, S. (2002). Donepezil for cognitive deficits following traumatic brain injury: A case report. Journal of Neuropsychiatry Clinical Neuroscience, 14, 463-464.
7. Braida, D., Paladini, E., Griffini, P., Lamperti, M., Colibretti, L., & Sala, M. (1998). Long-lasting antiamnesic effect of a novel anticholinesterase inhibitor (MF 268). Pharmacology, Biochemistry, and Behavior, 59, 897-901.
8. Buccafusco, J. J., Jackson, W. J., Stone, J. D., & Terry, A. V. (2003). Sex dimorphisms in the cognitive-enhancing action of the Alzheimer's drug donepezil in aged rhesus monkeys. Neuropharmacology, 44, 381-389.
9. Buchanan, R. W., Summerfelt, A., Tek, C., & Gold, J. (2002). An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophrenia Research, 59, 29-33.
10. Bullock, R., & Dengiz, A. (2005). Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. International Journal of Clinical Practice, 59, 817-822.
11. Carr, E. G., & Durand, V. M. (1985). Reducing behavior problems through functional communication training. Journal of Applied Behavior Analysis, 18, 111-126.
12. Chez, M. G., Aimonovitch, M. C., Buchanan, M. S., Mrazek, S. R., & Tremb, R. J. (2004). Treating autistic spectrum disorders in children: Utility of the cholinesterase inhibitor rivastigmine tartrate. Journal of Child Neurology, 19, 165-169.
13. Chez, M. G., Buchanan, T. M., Becker, M., Kessler, J., Aimonovitch, M. C., & Mrazek, S. R. (2003). Donepezil hydrochloride: A double-blind study in autistic children. Journal of Pediatric Neurology, 1, 83-88.
14. Conners, C. K., Levin, E. D., Sparrow, E., Hinton, S. C., Erhardt, D., Meck, W. H., et al. (1996). Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacology Bulletin, 32, 67-73.
15. Cooper J. R., Bloom F. E., & Roth R. H. (1996). The biochemical basis of neuropharmacology (pp. 190-219). New York: Oxford University Press.
16. Court, J. A., Martin-Ruiz, C., Graham, A., & Perry, E. (2000). Nicotinic receptor in human brain: Topography and pathology. Journal of Chemical Neuroanatomy, 20, 281-298.
17. Coyle, J. T., Price, D. L., & de Long, M. R. (1983). Alzheimer's disease: A disorder of cortical cholinergic innervation. Science, 219, 1184-1190.
18. Csernansky, J. G., Martin, M., Shah, R., Bertchume, A., Colvin, J., & Dong, H. (2005). Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice. Neuropsychopharmcology, 8, [Epub ahead of print]
19. Davis, R. E., Doyle, P. D., Carroll, R. T., Emmerling, M. R., & Jaen, J. (1995). Cholinergic therapies for Alzheimer's disease. Arzneimittelforschung Drug Research 45, 425-431.
20. Davis, P., & Maloney, A. J. (1976). Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet, 2, 1403.
21. Dong, H., Csernansky, C. A., Martin, M. V., Bertchume, A., Vallera, D., & Csernansky, J. G. (2005). Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease. Psychopharmacology, 19, [E-pub ahead of print]
22. Ellis, C. R., Singh, N. N., & Ruane, A. L. (1999). Nutritional, dietary, and hormonal treatments for individuals with mental retardation and developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 335-341.
23. Erickson, S. K., Schwarzkopf, S. B., Palumbo, D., Badgley-Fleeman, J., Smirnow, A. M., & Light G. A. (2005). Efficacy and tolerability of low-dose donepezil in schizophrenia. Clinical Neuropharmacology, 28, 179-184.
24. Foldi, N. S., White, R. E. C., & Schaefer, L. A. (2005). Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer's disease. International Journal of Geriatric Psychiatry, 20, 485-488.
25. Food and Drug Administration, Aricept (donepezil hydrochloride tablets). Retrieved August 2003, from http,//www.fda.gov/cder/foi/label/2001/20690s16lbl. pdf, 2000, December.
26. Freudenreich, O., Herz, L., Deckersbach, T., Evins, A. E., Henderson, D. C., Cather. C., et al. (2005). Added donepezil for stable schizophrenia: A double-blind, placebo-controlled trial. Psychopharmacology, 19, [E-pub ahead of print]
27. Frick, K. M., Stearns, N. A., Pan, J. Y., & Berger-Sweeney, J. (2003). Effects of environmental enrichment on spatial memory and neurochemistry in middle-aged mice. Learning and Memory, 10, 187-198.
28. Friedman, J. I., Adler, D. N., Howanitz, E., Harvey, P. D., Brenner, G., Temporini, H., et al. (2002). A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biological Psychiatry 51, 349-357.
29. Giacobini, E. (1993). Pharmacotherapy of Alzheimer's disease: New drugs and novel strategies. Progress in Brain Research, 98, 447-454.
30. Graham, A. J, Martin-Ruiz, C. M., Teaktong, T., Ray, M. A., & Court, J. A. (2002). Human brain nicotinic receptors, their distribution and participation in neuropsychiatric disorders. Current Drug Targets. CNS and Neurological Disorders, 1, 387-397.
31. Hardan, A. Y., & Handen, B. L. (2002). A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 12, 237-241.
32. Harris, N. S., Courchesne, E., Townsend, J., Carper, R. A., & Lord, C. (1999). Neuroanatomic contributions to slowed orienting of attention in children with autism. Cognitive Brain Research, 8, 61-71.
33. Hashimoto, M., Kazui, H., Matsumoto, K., Nakano, Y., Yasuda, M., & Mori, E. (2005). Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? American Journal of Psychiatry, 162, 676-682.
34. Hayes, R. L, Lyeth, B. G., & Jenkins, L. W. (1989). Neurochemical mechanisms of mild and moderate head injury: Implications for treatment. In H. A. Levin, H. M. Eisenberg, & A. L. Benton (Eds.), Mild head injury (pp. 54-59). New York: Oxford University Press.
35. Heller, J. H., Spiridigliozzi, G. A., Doraiswamy, P. M., Sullivan, J. A., Crissman, B. G., & Kishnani, P. S. (2004). Donepezil effects on language in children with Down syndrome: Results of the first 22-week pilot clinical trial. American Journal of Medical Genetics, 130A, 325-326.
36. Heller, J. H., Spiridigliozzi, G. A, Sullivan, J. A., Doraiswamy, P. M., Krishnan, R. R., & Kishnani, P. S. (2003). Donepezil for the treatment of language deficits in adults with Down syndrome: A preliminary 24-week open trial. American Journal of Medical Genetics, 116A, 111-116.
37. Hertzman, M. (2003). Galantamine in the treatment of adult autism: A report of three clinical cases. International Journal of Psychiatry in Medicine 33, 395-398.
38. Hohmann, C. F., & Berger-Sweeney, J. (1998). Cholinergic regulation of cortical development and plasticity: New twists to an old story. Perspectives on Developmental Neurobiology, 5, 401-425.
39. Hoopes, S. P. (1999). Donepezil for Tourette's disorder and ADHD. Journal of Clinical Psychopharmacology, 19, 381-382.
40. Howard, A. K., Thornton, A. E., Altman, S., & Honer, W. G. (2002). Donepezil for memory dysfunction in schizophrenia. Journal of Psychopharmacology, 16, 267-270.
41. Kahng, S., Iwata, B. A., & Lewin, A. B. (2002). The impact of functional assessment on the treatment of self-injurious behavior. In S. R. Schroeder, M. L. Oster-Granite, & T. L. Thompson (Eds.), Self-injurious behavior: Gene-brain-behavior relationships (pp. 119-131). Washington, DC: American Psychological Association
42. Kandel, E. R. (2001). The molecular biology of memory storage: A dialogue between genes and synapses. Science, 294, 1030-1038.
43. Kaye, N. S., Townsend, J. B., & Ivins, R. (2003). An open-label trial of donepezil (Aricept) in the treatment of persons with mild traumatic brain injury. Journal of Neuropsychiatry and Clinical Neuroscience, 15, 383-384.
44. Khateb, A., Ammann, J., Annoni, J. M., & Diserens, K. (2005). Cognition-enhancing effects of donepezil in traumatic brain injury. European Neurology, 54, 39-45.
45. Kishnani, P. S., Sullivan, J. A., Walter, B. K., Spiridigliozzi, G., Doraiswamy, P. M., & Krishnan, K. R. R. (1999). Cholinergic therapy for Down's syndrome. Lancet, 353, 1064-1065.
46. Kondoh, T., Amamoto, N., Doi, T., Hamada, H., Ogawa, Y., Nakashima, M., et al. (2005). Dramatic improvement in Down syndrome-associated cognitive impairment with donepezil. Annals of Pharmacotherapy, 39, 563-566.
47. Kosasa, T., Kuriya, Y., Matsui, K., & Yamanishi, Y. (1999). Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats. European Journal of Pharmacology, 10, 7-13.
48. Krnjevic, K., & Reinhardt, W. (1979). Choline excites cortical neurons. Science, 206, 1321-1323.
49. Lee, M., Martin-Ruiz, C., Graham, A., Court, J., Jaros, E., Perry, R., et al. (2002). Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain, 125, 1483-1495.
50. Levin, E. D. (1992). Nicotinic systems and cognitive function. Psychopharmacology, 108, 417-431.
51. Levin, E. D. (2000). The role of nicotinic acetylcholine receptors in cognitive function. In F. Clementi, D. Fornasari, & C. Gotti (Eds.), Neuronal nicotinic receptors: Experimental pharmacology (pp. 587-602). Berlin: Springer.
52. Levin, E. D., Conners, C., Sparrow, E., Hinton, S., Erhardt, D., & Meck, W., et al. (1996). Nicotine effects on adults with attention deficit hyperactivity disorder. Psychopharmacology, 123, 55-63.
53. Levin, E. D., Lee, C., Rose, J. E., Reyes, A., Ellison, G., Jarvik, M., & Gritz, E. (1990). Chronic nicotine and withdrawal effects on radial arm maze performance in rats. Behavioral and Neural Biology, 53, 269-276.
54. Levin, E. D., & Torry, D. (1996). Acute and chronic nicotine effects of working memory in aged rats. Psychopharmacology, 123, 217-230.
55. Lindsay, R. L., & Aman, M. M. (2003). Pharmacologic therapies aid treatment for autism. Pediatric Annals, 32, 671-676.
56. Lott, I. T., Osann, K., Doran, E., & Nelson, L. (2002). Down syndrome and Alzheimer disease, response to donepezil. Archives of Neurology, 59, 1133-1136.
57. Luine, V. N., Mohan, G., Tu, Z., & Efange, S. M. N. (2002). Chromaproline and chromaperidine, nicotine agonists, and donepezil cholinesterase inhibitor, enhance performance of memory tasks in ovariectomized rats. Pharmacology, Biochemistry, and Behavior, 74, 213-220.
58. MacEwan, G. W., Ehmann, T. S., Khanbhai, I., & Wrixon, C. (2001). Donepezil in schizophrenia - is it helpful? An experimental design case study. Acta Psychiatrica Scandinavica, 104, 469-471.
59. Mann, E. M. A. (1988). Alzheimer's disease and Down's syndrome. Histopathology, 13, 125-137.
60. Mann, E. M. A., & Esiri, M. M. (1989). The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. Journal of the Neurological Sciences, 89, 169-179.
61. Masanic, C. A., Bayley, M. T., van Reekum, R., & Simard, M. (2001). Open-label study of donepezil in traumatic brain injury. Archives of Physical Medicine and Rehabilitation, 82, 896-901.
62. McCracken, J. T., McGough, J., Shah, B, Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N. M., Grados, M., Vitiello, B., Ritz, L., Davies, M., Robinson, J., & McMahon, D. (Research Units on Pediatric Psychopharmacology Autism Network). (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347, 314-321.
63. McDonald, M. P., & Overmeier, J. B. (1998). Present imperfect: A critical review of animal models of the mnemonic impairments in Alzheimer's disease. Neuroscience & Biobehavioral Reviews, 22, 99-120.
64. McEachin, J. J., Smith, T., & Lovaas, O. I. (1993). Long-term outcome for children with autism who received early intensive behavioral treatment. American Journal on Mental Retardation, 97, 359-72.
65. Meyer, J. S., Chowdhury, M. H., Xu, G., Li, Y., & Wuach, M. (2002). Donepezil treatment of vascular dementia. Annals of the New York Academy of Sciences, 977, 482-486.
66. Mirza, N. R., & Stolerman, I. P. (2000). The role of nicotinic and muscarinic acetylcholine receptors in attention. Psychopharmacologia, 148, 243-250.
67. Morey, C. E., Cilo, M., Berry, J., & Cusik, C. (2003). The effect of Aricept® in persons with persistent memory disorder following traumatic brain injury: A pilot study. Brain Injury, 17, 809-815.
68. Mori, S. (2002). Response to donepezil in Alzheimer's disease and Parkinson's disease. Annals of the New York Academy of Sciences, 977, 493-500.
69. Myhrer, T. (2003). Neurotransmitter systems involved in learning and memory in the rat: A meta-analysis based on studies of four behavioral tasks. Brain research. Brain research reviews, 41, 268-287.
70. Nahas, Z., George, M. S., Horner, M. D., Markowitz, J. S., Li, X., & Lorberbaum, J. P., et al. (2003). Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: A pilot double-blind placebo controlled BOLD fMRI study. Neurocase, 9, 274-282.
71. Narahashi, T., Moriguchi, S., Zhao, X., Marszalec, W., & Yeh, J. Z. (2004). Mechanisms of action of cognitive enhancers on neuroreceptors. Biological & Pharmaceutical Bulletin, 27, 1701-1706.
72. National Institute of Mental Health, CGI (Clinical Global Impression) scale. (1985). Psychopharmacology Bulletin, 21, 839-843.
73. Niederhofer, H., Staffen, W., & Mair, A. (2002). Galantamine may be effective in treating autistic disorder. British Journal of Medicine, 325, 1422.
74. Newhouse, P. A., Potter, A., Corwin, J., & Lenox, R. (1992). Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology, 108, 480-484.
75. Nicolodi, M., Galeotti, N., Ghelardini, C., Cartolini, A., & Sicuteri, F. (2002). Central cholinergic challenging of migraine by testing second-generation anticholinesterase drugs. Headache, 42, 596-602.
76. Nordberg, A. (2001). Nicotinic receptor abnormalities of Alzheimer's disease: Therapeutic implications. Biological Psychiatry, 49, 200-210.
77. Owley, T., McMahon, W., Cook, E. H., Laulhere, T., South, M., & Mays, L. Z., et al. (2001). Multisite, double-blind, placebo-controlled trial of porcine secretin in autism. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 1293-1299.
78. Owley, T., Steele, E., Corsello, C., Risi, S., McKaig, K., & Lord, C., et al. (1999). A double-blind, placebo-controlled trial of secretin for the treatment of autistic disorder. Medscape General Medicine, October, E2.
79. Paterson, D., & Nordberg, A. (2000). Neuronal nicotinic receptors in the human brain. Progress in Neurobiology, 61, 71-111.
80. Perry, E. K., Lee, M. L. W., Martin-Ruiz, C. M., Court, J. A., Volsen, S. G., & Merrit, J., et al. (2001). Cholinergic activities in autism, Abnormalities in the cerebral cortex and basal forebrain. American Journal of Psychiatry, 158, 1058-1066.
81. Perry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H., Perry, R. H. (1978). Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. British Medical Journal, 2, 1457-1459.
82. Prasher, V. P., Adams, C., Holder, R., & Down Syndrome Research Group. (2003). Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome, Open label study. International Journal of Geriatric Psychiatry, 18, 549-551.
83. Prasher, V. P., Huxley, A., & Haque, M. S. (2002). The Down syndrome ageing study group, A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease - pilot study. International Journal of Geriatric Psychiatry, 17, 270-278.
84. Pratt, R. D., Perdomo, C. A., Surick, I. W., & Ieni, J. R. (2002). Donepezil, tolerability and safety in Alzheimer's disease. International Journal Clinical Practice, 56, 710-717.
85. Pratt, R. D., & Perdomo, C. A., & The donepezil VaD 307 and 308 study groups. (2002). Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Annals of the New York Academy of Sciences, 977, 513-522.
86. Prickaerts, J., ŞIk, A., van der Staay, F. J., de Vente, J., & Blokland, A. (2005). Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: Acquisition versus consolidation. Psychopharmacology, 177, 381-390.
87. Reed, P., & Gibson, E. (2005). The effect of concurrent task load on stimulus over-selectivity. Journal of Autism Developmental Disorders, 35, 601-614.
88. Risch, S. C., McGurk, S., Horner, M. D., Nahas, Z., Owens, S. D., & Molloy, M., et al. (2001). A double-blind pacebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient, Functional MRI correlates. Neurocase, 7, 105-110.
89. Rogers, S. L., Doody, R. S., Mohs, R. C., Friedhoff, L. T., & The donepezil study group. (1998a). Donepezil improves cognition and global function in Alzheimer disease. Archives of Internal Medicine, 158, 1021-1031.
90. Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R. C., Friedhoff, L. T., & The donepezil study group. (1998b). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology, 50, 136-145.
91. Rogers, S. L., & Friedhoff, L. T. (1998). Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicenter open label extension study. European Neuropsychopharmacology, 8, 67-75.
92. Rogers, S. L., Friedhoff, L. T., & The donepezil study group. (1996). The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia, 7, 293-303.
93. Rogers, S. L., Yamanishi, Y., & Yamatsu, K. (1991). E2020-The pharmacology of a piperidine cholinesterase inhibitor. In R. Becker & E. Giacobini (Eds.), Cholinergic basis for Alzheimer therapy (pp. 314-320). Boston: Birkhauser.
94. Rosenthal, R. (1991). Meta-analysis: A review. Psychosomatic Medicine, 53, 247-271.
95. Rosenzweig, M. R., & Bennett, E. L. (1996). Psychobiology of plasticity. Effects of training and experience on brain and behavior. Behavioural Brain Research, 78, 57-65.
96. Rupniak, N. M. J., Tye, S. J., & Field, M. J. (1997). Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. Psychopharmacology, 131, 406-410.
97. Rusted, J., Graupner, L., O'Connell, N., & Nicholls, C. (1994). Does nicotine improve cognitive function? Psychopharmacology, 115, 547-549.
98. Sarter, M., & Bruno, J. P. (1999). Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders. Trends in Neuroscience, 22, 67-74.
99. Schupf, N., Kapell, D., Nightingale, B., Rodriguez, A., Tycko, B., & Mayeux, R. (1998). Earlier onset of Alzheimer's disease in men with Down syndrome. Neurology, 40, 991-995.
100. Seltzer, B., Zolnouni, P., Nunez, M., Goldman R, Kumar, D., & Ieni, J., et al. (2004). Efficacy of donepezil in early-stage Alzheimer disease: A randomized placebo-controlled trial. Archives of Neurology, 61, 1852-1856.
101. Smith, T., Eikeseth, S., Klevstrand, M., & Lovaas, O. I. (1997). Intensive behavioral treatment for preschoolers with severe mental retardation and pervasive developmental disorder. American Journal on Mental Retardation, 102, 238-249.
102. Smith, T. (1999). Outcome of early intervention for children with autism. Clinical Psychology: Science and Practice, 6, 33-49.
103. Sokol, D. K., Dunn, D. W., Edwards-Brown, M., & Feinberg, J. (2002). Hydrogen proton magnetic resonance spectroscopy in autism: Preliminary evidence of elevated choline/creatine ratio. Journal of Child Neurology, 17, 245-249.
104. Spowart-Manning, L., & van der Staay, F. J. (2004). The T-maze continuous alternation task for assessing the effects of putative cognition enhancers in the mouse. Behavioural Brain Research, 151, 37-46.
105. Spowart-Manning, L., & van der Staay, F. J. (2005). Spatial discrimination deficits by excitotoxic lesions in the Morris water escape task. Behavioural Brain Research, 156, 269-276.
106. Stahl, S. M. (2000). Essential psychopharmacology: Neuroscientific basis and practical applications. New York: Cambridge University Press.
107. Stryjer, R., Strous, R., Bar, F., Werber, E., Shaked, G., & Buhiri, Y., et al. (2003). Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clinical Neuropharmacology, 26, 12-17.
108. Sugimoto, H. (2001). Donepezil hydrochloride, a treatment drug for Alzheimer's disease. Chemical Reactions, 1, 63-73.
109. Takahata, K., Minami, A., Kusumoto, H., Shimazu, S., & Yoneda, F. (2005). Effects of selegiline alone or with donepezil on memory impairment in rats. European Journal of Pharmacology, 518, 140-144.
110. Taverni, J. P., Seliger, G., & Lichtman, S. W. (1998). Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation. Brain Injury, 12, 77-80.
111. Tenovuo, O. (2005). Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury - clinical experience in 111 patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 29, 61-67.
112. Tokita, K., Yamazaki, S., Yamazaki, M., Matsuoka, N., & Mutoh, S. (2002). Combination of a novel antidementia drug FK 960 with donepezil synergistically improves memory deficits in rats. Pharmacology, Biochemistry, and Behavior, 73, 511-519.
113. Tsai, L. Y. (1999). Pharmacology in autism. Psychosomatic Medicine, 61, 651-665.
114. Tsukada, H., Nishiyama, S., Fukumoto, D., Ohba, H., Sata, K., & Kakiuchi, T. (2004). Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: Functional imaging of the conscious monkey brain using animal PET in combination with microdialysis. Synapse, 52, 1-10.
115. Tuǧal, Ö., YazIcI, K. M., YaǧcIoǧlu, A. E. A., & Göǧüş, A. (2004). A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. International Journal of Neuropsychopharmacology, 7, 117-123.
116. Van Dam, D., Abramowski, D., Staufenbiel, M., & De Deyn, P. P. (2005). Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology, 180, 177-190.
117. Van Reekum, R., Black, S.E., Conn, D., & Clarke, D. (1997). Cognition-enhancing drugs in dementia: A guide to the near future. Canadian Journal of Psychiatry, 42, 35S-50S.
118. Walker, W., Seel, R., Gibellato, M., Lew, H., Cornis-Pop, M, & Jena, T., et al. (2004). The effects of donepezil on traumatic brain injury acute rehabilitation outcomes. Brain Injury, 18, 739-750.
119. Whelan, F. J., Walker, M. S., & Schultz, S. K. (2000). Donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury. Annals of Clinical Psychiatry, 12, 131-135.
120. White, K. G., & Ruske, A. C. (2002). Memory deficits in Alzheimer's disease: The encoding hypothesis and cholinergic function. Psychonomic Bulletin & Review, 9, 426-437.
121. Whitehead, A., Perdomo, C., Pratt, R. D., Birks, J., Wilcock, G. K., & Evans, J. G. (2004). Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: A meta-analysis of individual patient data from randomised controlled trials. International Journal of Geriatric Psychiatry, 19, 624-633.
122. Whitlock, J. (1999). Brain injury, cognitive impairment, and donepezil. Journal of Head Trauma Rehabilitation, 14, 424-427.
123. Wilens, T. E., Biederman, J., Wong, J., Spencer, T. J., & Prince, J. B. (2000). Adjunctive donepezil in attention deficit hyperactivity disorder youth: Case series. Journal of Child and Adolescent Psychopharmacology, 10, 217-222.
124. Williams, D. C., & Saunders, K. J. (1997). Methodological issues in the study of drug effects on cognitive skills in mental retardation. International Review of Research in Mental Retardation, 21, 147-185.
125. Zhang, L., Plotkin, R. C., Wang, G., Sandel, E., & Lee, S. (2004). Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Archives of Physical Medicine and Rehabilitation, 85, 1050-1055.
126. Zhang, L., Zhou, F. M., & Dani, J. A. (2004). Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Molecular Pharmacology, 66, 538-544.
127. Zigman, W. B., Schupf, N., Devenny, D. A., Miezejeski, C., Ryan, R., & Urv, T. K., et al. (1995). Incidence and prevalence of dementia in adults with and without Down syndrome. American Journal on Mental Retardation, 100, 403-412.